Cancer Commons is a non-profit network of patients, physicians, and scientists from many disciplines. We identify the knowledge needed to get the best possible outcomes, and continuously refine it based on clinical results and breaking research.
Help you choose the right physician. This is the most important decision you’ll make.
Find the best treatments and trials for you.
Connect you directly with researchers who may have promising investigational therapies.
Send you personalized alerts based on discoveries for patients like you.
(Free and confidential)
Q I was diagnosed with stage IIB adenocarcinoma of the lung in July 2013. I underwent a lobectomy, followed by cisplatin/alimta and radiation therapy. In October 2014, a brain metastasis was found in my parietal lobe, and excised by craniotomy and then treated with SRS. In January 2015, my doctor found a cerebellar brain met, which we treated with SRS then surgical removal. In October 2015 this area had to be re-irradiated, and now in January 2016, my MRI showed that it is enlarged, and there is a new tumor in the frontal lobe. My neurosurgeon thinks that the old spot is “pseudo-progression,” but the new tumor is real. My radiation oncologist said no more radiation to the brain. There were no mutations found in any of my tumors; my oncologist thinks I should find a clinical trial. Any suggestions for relevant trials in Florida?
A Brain metastases limit your eligibility for some trials, unfortunately, but several trials might be a good fit if your new brain lesion is asymptomatic. Below is a list of trials in FL, all of which either accept patients with asymptomatic mets, like you, or don’t mention brain metastases as one of the exclusion criteria:
NCT02000947: Combines MEDI4736 and tremelimumab, two promising immunotherapy drugs. In Tampa.
NCT02423343: Combines galunisertib (a targeted drug) with the immunotherapy drug nivolumab (Opdivo). Nivolumab is approved for lung cancer, and may work even better when combined with a second drug that acts in a different way. In Tampa.
NCT02451930: Combines necitumumab, a targeted drug, with Keytruda. In Fort Myers and St. Petersburg.
NCT02309177: Tests nivolumab and chemotherapy. In Tampa.
NCT02646748: Combines Keytruda with a targeted drug. In Port St. Lucie.
If a solution is known, we’ll find it. We use informatics to find what works best for you, eliminating the huge disparities in knowledge across physicians and institutions.
If there’s no known solution, we’ll help you find one. We search thousands of clinical trials and case studies with off-label drugs to identify novel treatments tailored for you.
What we discover for you is immediately shared with similar patients. We aggregate data from thousands of patients to explore treatment alternatives far more efficiently than clinical trials.
Cancer is thousands of distinct, molecular diseases, with hundreds of potential treatments. Experts seldom agree on the optimal way to treat any cancer. Cancer Commons levels the playing field by bringing the world’s collective knowledge and resources to each patient and continuously refining that knowledge based on clinical results.
The time it takes for medical ideas to diffuse through the community when one misses a critical talk or paper.
The life expectancy of a patient with metastatic melanoma. This number has not changed in decades.
The variance of 5-year survival rates for similar patients depending on where they are treated and by whom.
The number of lives we estimate can be saved annually by optimizing and expanding the use of available drugs.
We need you! Cancer Commons is supported by volunteers interacting with patients,
researching treatment options, curating information, writing code, or raising funds.
From patient stories to the latest trials, stay on the top of the most important cancer news.
Read all the latest news for Breast Cancer, Lung Cancer, Melanoma,
Neuroendocrine Tumors, and Prostate Cancer
Cancer Commons | Oct 25 2016
Lance Williams was diagnosed with head and neck cancer in 2012. Since then, he has undergone multiple lines of treatment…
More Super Patients:
Super ASK Patient: Dyanne and Lars Push Far Beyond Standard Lung Cancer Treatment
Emma Shtivelman, PhD | Nov 10, 2016
Last year, the U.S. Food and Drug Administration (FDA) approved two anti-PD-1 checkpoint inhibitors, a type of immunotherapy…